CytoDyn's Days Sales Outstanding for the
three
months ended in Feb. 2026 was 0.
CytoDyn's Days Inventory for the
three
months ended in Feb. 2026 was 0.
CytoDyn's Days Payable for the
three
months ended in Feb. 2026 was 0.
Therefore, CytoDyn's Cash Conversion Cycle (CCC) for the
three
months ended in Feb. 2026 was 0.00.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
CytoDyn Cash Conversion Cycle Related Terms
CytoDyn Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for CytoDyn's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:296 vs VSTM, IRD, PALI: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, CytoDyn's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where CytoDyn's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
CytoDyn's Cash Conversion Cycle for the fiscal year that ended in May. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn (STU:296) has a Cash Conversion Cycle of 0.00 as of Feb. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on CytoDyn and its competitors.
Is CytoDyn's Cash Conversion Cycle too high?
CytoDyn's current Cash Conversion Cycle is 0.00. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Cash Conversion Cycle compare to VSTM and IRD?
CytoDyn's Cash Conversion Cycle of 0.00 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.45, based on 870 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on CytoDyn and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoDyn's current Cash Conversion Cycle is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Cash Conversion Cycle of 0.00. The current Cash Conversion Cycle is 0.00. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For CytoDyn (STU:296), the current Cash Conversion Cycle is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score
Get the complete analysis for STU:296
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:296 has been successfully added to your 
